183
Views
24
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)

ORCID Icon, , , , , , , , , , , , , & show all
Pages 5517-5526 | Published online: 11 Sep 2021

References

  • Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032
  • Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a Retrospective Cohort Study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
  • Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Hear Lung Transplant. 2020;39(5):405–407. doi:10.1016/j.healun.2020.03.012
  • Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection — a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;1–14.
  • Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539. doi:10.1007/s00281-017-0629-x
  • Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:1.
  • Burrage DR, Koushesh S, Sofat N. Immunomodulatory drugs in the management of SARS-CoV-2. Front Immunol. 2020;11:1844.
  • Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-immunomodulatory therapy in COVID-19. Drugs. 2020;80(13):1267–1292. doi:10.1007/s40265-020-01367-z
  • Anon. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi:10.1056/NEJMoa2021436
  • Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645.
  • Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. Rheumatology (Oxford). 2018;57(suppl_1):i4–i11. doi:10.1093/rheumatology/kex453
  • Aimo A, Pascual Figal DA, Bayes-Genis A, Emdin M, Georgiopoulos G. Effect of low-dose colchicine in acute and chronic coronary syndromes: a systematic review and meta-analysis. Eur J Clin Invest. 2020;51(4):e13464.
  • Ravelli RBG, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004;428(6979):198–202. doi:10.1038/nature02393
  • Otani K, Watanabe T, Shimada S, et al. Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Sci Rep. 2016;6(1):1–10. doi:10.1038/srep32587
  • Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum. 2007;56(10):3183–3188. doi:10.1002/art.22938
  • Yousefi H, Mashouri L, Okpechi SC, Alahari N, Alahari SK. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: a review describing drug mechanisms of action. Biochem Pharmacol. 2021;183.
  • Perricone C, Bartoloni E, Gerli R. Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19. Reumatologia. 2020;58(5):261–264. doi:10.5114/reum.2020.100088
  • Vitiello A, Ferrara F, Ferrara F. Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med. 2021;178:106322. doi:10.1016/j.rmed.2021.106322
  • Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw open. 2020;3(6):e2013136. doi:10.1001/jamanetworkopen.2020.13136
  • Della-Torre E, Della-Torre F, Kusanovic M, et al. Treating COVID-19 with colchicine in community healthcare setting. Clin Immunol. 2020;217:108490.
  • Tardif J-C, Bouabdallaoui N, L’Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a Phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021;19:1–9.
  • Landray M. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021;2021.05.18.21257267.
  • World Health Organization. R&D blueprint and COVID-19. World Health Organization; 2020. Available from: https://www.who.int/teams/blueprint/covid-19. Accessed February 19, 2021.
  • Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial. medRxiv. 2020;2020.08.06.20169573.
  • Scarsi M, Piantoni S, Colombo E, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 2020;79(10):1286–1289. doi:10.1136/annrheumdis-2020-217712
  • Sandhu T, Tieng A, Chilimuri S, Franchin G. A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe covid-19 infection. Can J Infect Dis Med Microbiol. 2020;2020.
  • Brunetti L, Diawara O, Tsai A, et al. Colchicine to weather the cytokine storm in hospitalized patients with COVID-19. J Clin Med. 2020;9(9):2961. doi:10.3390/jcm9092961
  • Ivan T, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med. 2020;19:100290. doi:10.1016/j.obmed.2020.100290
  • Ivan T, Devina H, Halim A, Jodhinata C, Audi T, Andree Y. Colchicine treatment can improve outcomes of coronavirus 19): a systematic review and analysis. Clin Exp Pharmacol Physiol. 2021;6:823–830.